Skip to main content
. 2017 Jul 19;6(7):e005428. doi: 10.1161/JAHA.116.005428

Figure 2.

Figure 2

Calibration plot of observed vs predicted risk of potassium >5.5 mmol/L in the year following angiotensin‐converting enzyme inhibitor or angiotensin receptor blocker therapy by decile of predicted risk among patients in the (A) Stockholm Creatinine Measurements (SCREAM) development cohort (N=52 544), and (B) Geisinger Health System validation cohort (N=14 772). Reflects patients with baseline potassium levels <5 mmol/L.